Jump to content

Institut hospitalo-universitaire

From Wikipedia, the free encyclopedia
Institut hospitalo-universitaire
Founded2009
FounderNicolas Sarkozy
Location
Area served
Worldwide
Official languages
French, English
Key people
Nicholas Ayache, Didier Raoult
Websitewww.ihu-france.org

The Instituts hospitalo-universitaires (IHU) are medical training and research centers. They have been created by former French President Nicolas Sarkozy in 2009. The instituts hospitalo-universitaires are in partnership with universities (University of Paris, Sorbonne University, etc), hospitals as well as research laboratories both private and public.

They are located in Paris, Strasbourg, Marseille and Bordeaux.

The target is to be centers of excellence in French medical research, to train specialists in their fields of competence, to attract renowned researchers and to promote their work. Significant economic spinoffs are expected, indeed the institutes must allow "the development of innovative health products" by weaving partnerships and "increase the attractiveness of France for the health industries, thereby improving the efficiency of care by cost containment".[1][2]

In November 2021, IHU Méditerranée infection research centre in Marseille identified a COVID-19 SARS-CoV-2 variant under investigation, B.1.640.2, subsequently known as the IHU variant.[3]

In May 2022 the French medicines agency ANSM announced it would file charges against the Marseille IHU, run by Didier Raoult, for potentially criminal research misconduct during the COVID-19 pandemic.[4]

Notes

[edit]
  1. ^ (in French)ANR : Appel à projets Instituts Hospitalo-Universitaires (IHU) Archived 2014-01-08 at the Wayback Machine
  2. ^ (in French)Six «super-CHU» financés à hauteur de 850 millions
  3. ^ Zachary Snowdon Smith (5 January 2022). "Here's Why You Shouldn't Worry About IHU—The New Covid Variant In France—Yet, WHO Says". Forbes.
  4. ^ Casassus B (2022). "French research institute faces criminal charges over "serious breaches"". BMJ. 377: o1117. doi:10.1136/bmj.o1117. PMID 35508313.